March - 2021

Protein Target for Neuroblastoma

Australian researchers have discovered a new way to target an aggressive childhood cancer, neuroblastoma, one of the most common and...

Pediatric cancers have unique genetic vulnerabilities

Most cancer drugs that target specific genetic mutations are designed for adult cancers rather than those in children, partly because ...

ATRT molecular groups: looking at the biology from the clinic

Atypical teratoid rhabdoid tumor (ATRT) is a rare brain tumor that predominantly occurs in young children. Scientists at St. Jude...

Pediatric Cancer Survivors and Diabetes: What Are the Risks?

Diabetes and metabolic syndrome represent two of the most common long-term complications for survivors of childhood cancer. Approximately...

COVID-19 Impacting Caregivers of Children With Cancer

Caregivers of childhood cancer survivors are experiencing changes to medical care, financial disruptions, and emotional distress due to...

Natural "brake" against malignant neuroblastoma

The scientists discovered that the uncontrolled growth of benign neuroblastomas is stopped by a signal molecule produced by Schwann cells...

Origin of childhood cancer malignant rhabdoid tumour discovered

The first proof of the origin of malignant rhabdoid tumour (MRT), a rare childhood cancer, has been discovered by researchers at the ...

FDA Grants Orphan Drug Designation to Opaganib in Neuroblastoma

After my daughter's cancer, I wanted to control her entire life. Then she went to college.

When Childhood Cancer Survivors Face Sexual Challenges

Early interventions may improve long-term academic achievement in young childhood brain tumor survivors

Immunotherapy for children with primary liver carcinomas: Research offers new hope

Pediatric psychologist explains how to support your child's development after a cancer diagnosis

Adult Survivors of Childhood Cancer Have High Prevalence of Chronic Pain

Spontaneous Remission in Childhood Cancer Rare but Fleeting

First successful treatment of pediatric high-risk refractory neuroblastoma with PARP inhibition

Researchers identify malignant cells responsible for relapse in high-risk neuroblastoma